Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
The analysis included 3,048 propensity-matched participants (1:1) in each cohort
Read more: To view or add a comment, sign in Eli Lilly and Company A meaningful milestone in the future of obesity care Eli Lilly shared promising clinical trial results showing sustained weight loss over one year with an oral therapy in development, alongside submission to the FDA for obesity approval
Long-term adherence rates for oral vs
Outcome measures include frailty status using Fried criteria and Frailty Index accumulation of deficit, selected frailty biomarkers (interleukin-6, tumor necrosis factor-alpha, and insulin-like growth factor-1), physical function, cognitive function, nutritional status and biochemical profile
US$ 22.22
US$ 28.48
US$ 22.76
US$ 29.65
